CRVS: Corvus Pharmaceuticals, Inc.
Performance
CRVS +49.34%
Watchlist
Select an item
Summary
CRVS at a glance
CRVS returned +49.34% over the past year and +17.76% a year over five years. Its worst drop in that year was -63.24%, smaller than 10% of stocks on Redstone, and its Sharpe ratio of 0.71 beats 61% of stocks on Redstone. It pays no dividends.
Current Drawdown
-55.53%
Rolling Volatility
72.99%
Actions
Metrics
Risk Indicators
Alpha128.10%
Beta-0.10x
Sharpe0.71
Sortino2.70
Omega1.30
Calmar0.78
Martin3.09
Profile
About CRVS
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $955M
- Listed
- Mar 2016
- Employees
- 37
- Headquarters
- South San Francisco, CA
- Website
- corvuspharma.com
Comparisons